November 3, 2021 (NewsRx) – By a News Reporter-News Team Editor b Daily insurance news – Researchers publish new report on neurodegenerative diseases and conditions – Parkinson’s disease. According to a news report from Tel Aviv Israel, By NewsRx Journalists, Permanent Research, “Real-world data were used to describe prescription patterns for early anti-Parkinsonian drugs (FAPD) in Parkinson’s disease patients (PD) and to estimate the duration of the disease until levodopa (l-DOPA) treatment until death. “As related to the FAPD, by age group. The community cohort (2000-2012) included 6243 patients, members of an Israeli health maintenance organization.”
Funders for this study include National Institutes of Health (NIH) – U.S, European Commission, Howard Hughes Medical Institute.
The news reporters obtained a quote from the study from Tel Aviv University, “Time from FAPD acquisition up to 2 endpoints (l-DOPA acquisition and death) is calculated. Cox regressions were used to assess adjusted heart rate (HR) for each of the endpoints according to FAPD type, by age group. During a mean follow-up of 4.8 +/- 3.2 years A third of the group died. The percentage of l-DOPA use as a starting drug increased with age, while the percentage of dopamine (DAs) and monoamine oxidase B (MAO-BI) agonists decreased with age. Younger women were treated more often with DA as a starting drug. Compared to younger men At the age of 50 years, the time to onset of l-DOPA in the primary DA group was 4 times longer than in the primary MAO-BI group (HR, 0.23; 95% confidence interval, 0.08 -0.43; 1 / 0.23, 4.35) .All age groups showed a similar survival time trend associated with the type of primary drug.HRU combined age with primary l-DOPA group as a dialect reference group whose survival time was 2.4 times longer for the primary DA group (HR, 95% confidence interval 95%, 0.31-0.55; 1 / 0.41, 2.44), 1.9 times and 1.4 times for primary MAO-BI or amantadine, respectively. But may represent the severity of the disease During the prescription, and thus also affect the time of survival. “
According to news reports, the study concluded: “Real-world data illustrated that this choice also depends on age and gender.”
This study was peer-reviewed.
For more information on this study, see: Patterns of first-line medication in the real world of patients with Parkinson’s disease and duration of the disease: A large-scale follow-up study using a database of a health maintenance organization. Clinical neuropharmacology, 2021; 44 (5): 169-174. Clinical neuropharmacology You can contact us at: Lipincott Williams Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, Pennsylvania 19103, U.S.
Our news reports report that more information can be obtained by contacting Achinoam Faust-Sugar, Tel Aviv University, Tel Aviv Medical Center, Neurological Institute, Traffic Disorders Unit, Tel Aviv Israel. Additional authors for this study include Tanya Gurevitch, Nir Giladi, Violetta Rosani, Hava Peretz And Beatrice Hemo.
The Direct Object ID (DOI) for this additional information is: https://doi.org/10.1097/WNF.0000000000000461. This DOI is a link to an online electronic document that is free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports provide fact-based news about research and discoveries from around the world.)